Company intelligence / Profile preview

Renerval Biotherapeutics

Northcote, Victoria, Australiahpscreg.eu ↗

Ownership: Private
Development stage: Other

Overview

ReNerve develops proprietary medical devices and tissue-engineered products to accelerate peripheral nerve repair and regeneration. Its lead product, the NervAlign® Nerve Cuff, has received FDA clearance in the US and marketing approval in New Zealand. The company’s pipeline includes a range of next-generation biomaterial scaffolds (e.g., Nerve Guide Matrix) targeting improved outcomes after traumatic or surgical peripheral nerve injuries. Early clinical results are positive with strong animal model data supporting efficacy.

Therapeutic areas: NeurologyOther
Modalities: DeviceTissue-based medical devicePolymer-based scaffold
Industry: Therapeutic Medical Devices

Partnerships

Biomedical Europe B.V." (development/manufacturing)Yuan Yu" (commercialization/Taiwan)Collagen Solutions" (commercial partnership/Nerve Guide Matrix)

Beyond the preview

Go deeper on Renerval Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Renerval Biotherapeutics.

Explore the full profile